Markets:

Overview

News

Currencies

International

Treasuries

GoodRx Holdings, Inc. - Class A Common Stock (NQ:GDRX)

2.470 +0.110 (+4.66%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about GoodRx Holdings, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales ↗

February 27, 2025

GoodRx reported Q4 revenue of $198.6M, missing expectations. 2025 guidance projects $810M–$840M revenue and adjusted EBITDA of $270M–$286M.

Via Benzinga

GoodRx (NASDAQ:GDRX) Misses Q4 Revenue Estimates

February 27, 2025

Healthcare tech company GoodRx (NASDAQ:GDRX) missed Wall Street’s revenue expectations in Q4 CY2024, with sales flat year on year at $198.6 million. On the other hand, the company expects next...

Via StockStory

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

GoodRx Earnings: What To Look For From GDRX

February 26, 2025

Healthcare tech company GoodRx (NASDAQ:GDRX) will be announcing earnings results tomorrow before the bell. Here’s what investors should know.

Via StockStory

1 Healthcare Stock Primed for Growth and 2 to Avoid

February 17, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps have persisted in the wake of COVID-19 as players destocked inventories in 2023 and 2024....

Via StockStory

Topics Stocks

Assessing GoodRx Holdings: Insights From 4 Financial Analysts ↗

January 08, 2025

Via Benzinga

GoodRx Holdings Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) ↗

August 16, 2024

Via Benzinga

The Analyst Landscape: 7 Takes On GoodRx Holdings ↗

June 10, 2024

Via Benzinga

1 Healthcare Stock Primed for Growth and 2 to Snub

February 17, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Stocks

Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel ↗

December 12, 2024

Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and cardiovascular risk reduction.

Via Benzinga

How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals ↗

December 05, 2024

GoodRx's latest research shows surging demand for weight loss medications like Wegovy and Zepbound, despite high costs and limited insurance coverage, with consumers overspending $200 million in 2024.

Via Benzinga

Why GoodRx Holdings Stock Was Sinking This Week ↗

November 08, 2024

The company is growing key fundamentals. However, the improvements weren't enough to impress the market.

Via The Motley Fool

GoodRx (GDRX) Q3 2024 Earnings Call Transcript ↗

November 07, 2024

GDRX earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Forecasting The Future: 13 Analyst Projections For GoodRx Holdings ↗

May 16, 2024

Via Benzinga

Why GoodRx Surged Today ↗

March 25, 2024

The prescription-drug upstart got an upgrade from Wall Street.

Via The Motley Fool

GoodRx (GDRX) Q2 2024 Earnings Call Transcript ↗

August 08, 2024

GDRX earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

GoodRx Reports Q2 Earnings With Increased Prescription Revenue But Subscription Challenges ↗

August 08, 2024

GoodRx reported Q2 revenue of $200.61M, a 6% YoY increase. Prescription transactions revenue rose 7%, driven by 8% growth in Monthly Active Consumers. The company expects FY 2024 revenue at the lower...

Via Benzinga

MicroStrategy, Coinbase, Robinhood, Tesla And Other Big Stocks Moving Higher On Monday ↗

July 15, 2024

Via Benzinga

3 Lawsuit-Laden Stocks to Dump Before Problems Multiply ↗

July 10, 2024

These stocks to sell face ongoing and past litigation, but that isn't the only sticking point in their long-term prospects.

Via InvestorPlace

Market Correction Alert: Sell These 3 Tech Stocks While You Can ↗

June 28, 2024

These tech stocks to sell combine shaky operational outlooks with underlying fundamental shakiness that don't bode well for the long-term.

Via InvestorPlace

3 Stocks to Sell ASAP Before the June 27 Presidential Debate ↗

June 17, 2024

These stocks to sell sit within politically sensitive sectors, making them too risky to hold as we approach election season.

Via InvestorPlace

The 3 Most Undervalued Under-$10 Stocks to Buy in June 2024 ↗

June 04, 2024

These three, sub $10 stocks with enormous upside potential might just be your best investment nuggets this month.

Via InvestorPlace

GoodRx Strengthens Core Business With New Initiatives, Analyst Upgrades On Potential Opportunities ↗

May 23, 2024

GoodRx has been upgraded by RBC Capital Markets due to the growth potential from the Integrated Savings Program, direct contracting initiatives, and manufacturing solutions expansion.

Via Benzinga

GoodRx Shares Soar Nearly 10% As New Partnership With Kroger Promises Big Savings ↗

May 15, 2024

GoodRX shares surged nearly 10% Wednesday afternoon following the announcement of a new direct contracting agreement with Kroger Co. (NYSE:KR).

Via Benzinga

NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday ↗

May 15, 2024

Via Benzinga

GoodRx (GDRX) Q1 2024 Earnings Call Transcript ↗

May 09, 2024

GDRX earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

Change Healthcare Cyberattack: GoodRx Expects Low Single Digit Million-Dollar Impact In 2024 ↗

May 09, 2024

GoodRx's Q1 earnings: $0.08 EPS, sales hit $197.88 million, beating expectations fueled by prescription transactions and pharma solutions. Q2 forecast: ~$200 million revenue, optimistic 2024 outlook.

Via Benzinga

GDRX Stock Earnings: GoodRx Holdings Beats EPS, Beats Revenue for Q1 2024 ↗

May 09, 2024

GDRX stock results show that GoodRx Holdings beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

GoodRx Holdings Analyst Turns Bullish Ahead Of Q1 Earnings ↗

April 10, 2024

GoodRx Holdings Inc (NASDAQ: GDRX) got an upgrade last month from Wells Fargo analyst.

Via Benzinga

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 25, 2024

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

GoodRx Holdings, Inc. - Class A Common Stock (NQ:GDRX)

Headline News about GoodRx Holdings, Inc. - Class A Common Stock

Starting at $3.75/week.

Subscribe Today